Paricalcitol in Treating Patients With Myelodysplastic Syndrome
Recruitment status was: Active, not recruiting
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells.
PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
|Study Design:||Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes|
|Study Start Date:||May 2003|
- Determine the clinical effects of paricalcitol in patients with myelodysplastic syndromes.
- Determine whether this drug can improve RBC, WBC, or platelet counts in these patients.
- Determine whether this drug can decrease the risk of development of leukemia without causing undue toxicity in these patients.
OUTLINE: Patients receive oral paricalcitol daily for 4 months in the absence of disease progression or unacceptable toxicity.
Patients are followed at 1 month.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 8 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00064376
|United States, California|
|Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center|
|Los Angeles, California, United States, 90048|
|Study Chair:||H. Phillip Koeffler, MD||Cedars-Sinai Medical Center|